17th Annual European Life Sciences CEO Forum

FOR PARTNERING & INVESTMENT

28th - 29th of February 2024|HILTON ZURICH AIRPORT HOTEL | SWITZERLAND

20-MINUTE PRESENTERS:

Biotechnology

AM-Pharma B.V.

Utrecht, Netherlands

Wed 28 Feb · 14:20 – 10:30

AM-Pharma, a private clinical stage biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa as an enzyme replacement therapy administered sc for the rare disease hypophosphatasia, clinical PoC achieved, the compound can be on the market by 2030 and the market potential exceeds EURO 1B.

ARTHEx Biotech S.L.

Wed 28 Feb · 14:40 – 10:30

Arthex is a clinical-stage biotechnology company focusing developing innovative medicines for diseases with high unmet medical needs through the modulation of microRNAs. The Company’s lead investigational compound, ATX-01, is an antimiR designed to target microRNA 23b (miR-23b), which is associated with regulating the expression of muscleblind-like (MBNL) proteins involved in the pathogenesis of Myotonic dystrophy type 1. ATX-01 holds significant potential to deliver therapeutic benefit to DM1 patients, based on its dual mechanism of action that targets both toxic DMPK and MBNL proteins. ATX-01 is a very unique molecule with the potential to be best-in-class among the current landscape.

Biotechnology

Brainstorm Cell Therapeutics, Inc.

Burlington, United States

Wed 28 Feb · 13:40 – 10:30

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce debamestrocel (autologous MSC-NTF cells) through an exclusive, worldwide licensing agreement. Debamestrocel has Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BCLI is currently planning a phase 3b clinical trial of debamestrocel in ALS before market licensing application. BrainStorm has completed a Phase 3 trial in ALS; this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial of autologous MSC-NTF cells in progressive MS.

Brainstorm has developed an additional technology platform based on exosomes, Exosome MSC-NTF in advanced pre-clinical research and has been published. Exosome MSC-NTF has shown efficacy in two animal models of lung injury and in over 6 different in vitro models of inflammation, generating promising pre-clinical data of reduced inflammation and prevention of lung fibrosis. This platform compliments NurOwn as an allogenic product enabling the targeting of diseases with larger patient volumes for acute and preventative treatment.

Cantargia AB

Wed 28 Feb · 14:40 – 10:30

Development of antibody based therapeutics targeting IL1RAP. The target is involved of disease progression of both cancer as well as autoimmune/inflammatory disease. Lead asset: nadunolimab with positive phase 2a data in both NSCLC and PDAC. A phase 1/2 ongoing in triple negative breast cancer and phase 2/3 in preparation for first line therapy in pancreatic cancer. Second asset: CAN10 entering phase 1, in development for myocarditis and systemic sclerosis. Listed on NASDAQ Stockholm (CANTA).

Evaxion Biotech A/S

Hoersholm, Denmark

Wed 28 Feb · 13:40 – 10:30

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Biotechnology

Expert Systems, Inc.

San Duiego, United States

Thu 29 Feb · 11:35 – 10:30

Expert Systems is a hybrid AI/ML platform company where we combine human and artificial intelligence to accelerate drug discovery. Built from decades of proprietary experimental data and decades of expertise in early drug discovery, our expert systems' platform informs decision making and enables the selection of candidate drugs for clinical trials and research.

iOmx Therapeutics AG

Germany

Thu 29 Feb · 10:55 – 10:30

iOmx is a clinical-stage biotech company that harnesses deep tumor immunology insights to generate novel breakthrough I/O therapeutics for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of multi-functional powerful biologics with single-agent activity that overcome resistance in major solid tumors. By applying its comprehensive drug discovery & development expertise, iOmx is committed to shaping the future of cancer therapy. iOmx is backed by international venture capital investors, such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures as well as Arvantis. iOmx was founded in 2016 and is based in Munich.

Kamari Pharma Ltd.

Wed 28 Feb · 15:00 – 10:30

Kamari pharma is a clinical stage biotechnology company developing “First and Best in Class” treatments of rare and severe genetic dermatological diseases, such as Keratoderma and Ichthyosis. Kamari’s drugs are based on proprietary small molecules that modulate TRPV3, an ion channel that when overactivated or overexpressed, leads to severe skin diseases.. Kamari is developing both oral and topical drugs. The topical drug has just recently shown significant safety and efficacy in a phase 1b clinical trial in Keratoderma patients as demonstrated from topline results. This proof-of-concept study, held in centers in the UK and Israel, met its primary efficacy endpoint in almost all the treated patients (13 out of 15). In addition, the safety profile exhibited was very good. The topical TRPV3 inhibitor has also completed a phase 1 study in Lichen Simplex Chronicus-itch patients, in Germany, demonstrating excellent safety as well as efficacy trends. These novel “Best in Class” drugs are intended for helping patients with unmet needs, where efficacious treatments are currently unavailable. The untreated patient populations of Keratodermas and Ichthyosis are rare, yet still constitute a significant market opportunity. Kamari’s oral TRPV3 inhibitor, following proof of concept in animal models, will be advancing into clinical trials next year for treating keratoderma and severe and rare dermatological conditions such as Olmsted syndrome. Orphan designation protection by major regulatory agencies, in addition to a strong patent estate, will allow long terms market exclusivity. Kamari’s management team is composed of highly experienced individuals, with a track record of leading drug development programs through FDA approvals and financing their companies in the public equity markets. Kamari, funded by leading VCs, such as Pontifax, is now raising its next round of financing in order to secure the further development of its “Best in Class” high potential drugs.

Macomics Ltd.

UK

Thu 29 Feb · 10:35 – 10:30

Macomics is a macrophage drug discovery company, passionate about the therapeutic potential of targeting macrophages for better therapies. We are developing novel treatments for diseases where current therapeutics are severely limited or ineffective. Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology. Already proven in first-in-class target validation is oncology, ENIGMAC is a proprietary technology developed to produce gene editable microglia as well as macrophages. The platform can knock in or knock out genes of interest via CRISPRa or CRISPRi expression in iPSC derived cells, unlocking the opportunity for new target discovery informed by human data. For neurology disease-related drug discovery, Macomics has focused on lipid uptake effects on microglia to mimic inflammation combined with lipid loading. Now tested in several readouts including lysosomal function, cytokine release and phagocytosis it has designed a fully validated in vitro system.

MC2 Therapeutics A/S

Wed 28 Feb · 15:20 – 10:30

MC2 Therapeutics is developing novel treatment paradigms for immunology and inflammation (“I&I") diseases and has moved two first-in-class drug candidates with novel modes of action and multiple indication potential (“I&I pipeline in a product”) into phase 2 development. These are: MC2-32: Oral HSP90 Inhibitor targeting multiple pro-inflammatory pathways with unique profile releasing the full formidable effect of HSP90 in I&I without the class side effects. MC2-25: Iso-cyanate Scavenger for urea associated skin diseases MC2 is currently pursuing multiple indications where there are no or very limited approved treatment options including oral MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Chronic Kidney Disease-associated Pruritus (Ph2 enrollment completed, n=111) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing).

Biotechnology

Mestag Therapeutics Ltd.

Cambridge, United Kingdom

Wed 28 Feb · 15:00 – 10:30

Mestag harnesses new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease. Together with our collaboration partner Janssen Biotech, Inc. we are also identifying novel targets for future therapies. Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies.

Biotechnology

MetrioPharm AG

Zurich, Germany

Thu 29 Feb · 11:55 – 10:30

MetrioPharm is a Swiss clinical-stage biotech company that has developed a platform of oral small molecule immune modulators that normalize the pathologically dysregulated (reprogrammed) mitochondrial energy metabolism in macrophages and other immune cells without being immunosuppressive. This plays an important role in most inflammatory and infectious diseases. MetrioPharm's lead candidate MP1032 has a unique, self-regulating mechanism of action that makes it a first-in-class ROS (Reactive Oxygen Species) scavenger that reduces excessive intracellular ROS (intracellular oxidative stress) WITHOUT (!) interfering with the physiological (normal) ROS levels of other cells. ROS are essential for cell signaling. MP1032 has demonstrated broad-spectrum anti-inflammatory and antiinfectious activity in three completed Phase IIa clinical proof-of-concept studies in Psoriasis and COVID-19 involving a total of 234 patients treated with MP1032. In addition, MP1032 has shown strong efficacy data in preclinical in vivo studies in other inflammatory diseases such as Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Diseases, Sepsis and, most recently, Duchenne Muscular Dystrophy. As a monotherapy, MP1032 has therapeutic effects similar to corticosteroids, but without serious side effects. MP1032 in combination with ultra-low dose corticosteroids has the potential to replace the current standard of care, high dose corticosteroid therapy, with increased efficacy (2.5 times the high dose) and significantly reduced side effects. MP1032 has also demonstrated a broad host-directed antiviral and antibacterial activity in preclinical and clinical studies, which would be essential for improving future pandemic preparedness. MetrioPharm is initially focusing its anti-inflammatory drug development on rare diseases such as Duchenne Muscular Dystrophy. In this indication, patients are treated for many years or even decades with high-dose corticosteroids (cortisone-based therapeutics) as standard anti-inflammatory therapy, which typically leads to severe side effects. The focus on orphan indications is the fastest route to conditional marketing authorization by the EMA and accelerated approval by the FDA for MP1032.

Oryzon Genomics, S.A.

Spain

Wed 28 Feb · 14:00 – 10:30

A public clinical-stage biopharma company developing epigenetics for CNS disorders and oncology/hematology. c.50 highly-qualified professionals located in Barcelona, Boston and San Diego. Listed in Spain, aiming at NASDAQ-listing. Two uncorrelated clinical-stage compounds: vafidemstat (Phase III-ready, CNS) and iadademstat (Phase II, oncology/hematology). Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor, administered to + 425 subjects. The drug has shown promising results in reducing agitation/aggression in psychiatric patients in a Phase IIa basket trial, and in a global randomized, double blind Phase IIb trial in BPD (PORTICO, final results presented at ECNP-2024). Phase III in agitation/aggression in borderline personality disorder (BPD) in preparation. Vafidemstat is also being investigated for treating negative symptoms of schizophrenia in a randomized, double-blind Phase IIb trial (ongoing trial expansion to additional EU countries). Preparing a new Phase II trial in aggression in patients with ASD, including genetically-defined ASD subpopulations such as Phelan McDermid Syndrome. Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML, solid tumors and hematological disorders. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Highly encouraging data presented at ASH-2025 from ongoing trials in 1L AML (in combo with venetoclax/azacitidine, 100% ORR, 90% CR) and in R/RFlt3mut+ AML (in combo with gilteritinib, 67% CCR at the dose under expansion). Additional trials ongoing in MDS (in combo with azacitidine),1L SCLC (in combo with ICI), and in MPN (in combo with ASTX727). Expanding into hematological indications: sickle cell disease (PhIb trial approved by EMA, recruiting), essential thrombocythemia (PhII in prep).

Rinri Therapeutics Ltd.

Wed 28 Feb · 14:00 – 10:30

Rinri is the world’s leading company to be exploring the potential of a regenerative cell therapy for sensorineural hearing loss, and the only company to be addressing neural hearing loss.

Sapient Therapeutics Ltd.

Thu 29 Feb · 11:15 – 10:30

Sapient Therapeutics is a UK based biopharmaceutical company focused on neuroscience drug discovery and early clinical development. Our lead asset (SAP021) has completed a successful comparative Phase 1 study in 2023 and will move to the next phase of clinical development in 2024. SAP021 is a solid dose form of cannabidiol (CBD) for therapeutic use in treatment-resistant epilepsy and schizophrenia. Our leadership team is comprised of experienced neuroscience and cannabinoid medicine pharmaceutical professionals with a strategy to utilise the FDA 505(b)(2) regulatory pathway to bring new prescription medicines to patients with serious diseases in the shortest possible timeframe.

BiotechnologyPharmaceuticals/Licensing

TME Pharma

Berlin, Germany

Thu 29 Feb · 10:15 – 10:30

TME Pharma is a clinical-stage biotech company developing innovative therapies for aggressive cancers, focusing on the tumor microenvironment (TME). Our lead compound, NOX-A12, targets CXCL12 and has received Fast Track designation from the FDA for newly diagnosed, chemotherapy-resistant glioblastoma. In a Phase 1/2 trial, NOX-A12 combined with anti-VEGF and radiotherapy significantly increased survival compared to the standard of care reference cohort (p=0.003, Hazard Ratio: 0.30) and patients receiving NOX-A12 with radiotherapy alone (p=0.021, Hazard Ratio: 0.34). Median survival improved from 9.5 months to 19.9 months. A randomized, controlled Phase 2 trial is approved in the US and Germany to test multiple doses of NOX-A12 with anti-VEGF and radiotherapy. NOX-E36, our second clinical-stage asset, has demonstrated safety, tolerability, and promising pharmacokinetics/pharmacodynamics (PK/PD) as an anti-fibrotic treatment in ophthalmology. We plan to monetize NOX-E36 through a spinout or similar structure.

Vaccentis AG

Zrich, Switzerland

Wed 28 Feb · 15:20 – 10:30

Vaccentis AG is a Zurich-based company focused on the biotech and pharmaceutical sector. All research, development and clinical activities are carried out by a highly specialised subsidiary, VCC MEDICAL. VCC MEDICAL DIVISION IS DEVELOPING CLINICALLY PROVEN PRODUCTS, SHOWN TO MAINTAIN REMISSION AND ALLEVIATE DISEASE VCC-001 cancer vaccine Phase III data in Renal Cell Cancer has demonstrated clinical effect and was well tolerated, a disease with few current treatment options VCC-001 cancer vaccine concept has significant potential in colon and pancreatic cancers.

Pharmaceuticals/Licensing

Vidac Pharma Holding PLC

London, United Kingdom

Wed 28 Feb · 14:20 – 10:30

Vidac Pharma is a clinical-stage biopharmaceutical company advancing first-in-class oncology and onco-dermatology therapies based on a novel approach to cancer metabolism.

The company’s research focuses on targeting abnormal metabolic processes that characterize cancer cells, with the objective of restoring normal cellular regulation and inhibiting tumor progression. Vidac’s scientific platform targets the Warburg effect and forms the foundation of its clinical development programs and pipeline.

Founded in 2012, Vidac Pharma is led by Prof. Max Herzberg and a multidisciplinary leadership team with extensive experience in drug development, life sciences, and corporate management. The company is supported by an international network of scientific and clinical advisors.

Vidac’s lead compound, VDA-1102, is in clinical development for actinic keratosis and cutaneous T-cell lymphoma (CTCL). A next-generation candidate, VDA-1275, is currently in preclinical development, with potential application across a range of solid tumors.

Vidac Pharma maintains a strong intellectual property portfolio and operates within a structured governance and quality framework appropriate for a publicly traded life sciences company.

Vidac Pharma Holding PLC (T9G) is publicly traded on Xetra (Frankfurt Stock Exchange) and the Tradegate Exchange (Germany).

10-MINUTE PRESENTERS:

BiotechnologyMedical DevicesPharmaceuticals/Licensing

AATec Medical GmbH

Planegg-Martinsried, Germany

Wed 28 Feb · 14:30 – 10:30

AATec develops novel biopharmaceuticals for major respiratory inflammatory diseases such as COPD, bronchiectasis, asthma, and respiratory infections. The first indication for clinical development will be non-CF bronchiectasis. Our product platform is based on a novel version of alpha-1 antitrypsin for inhalation, a multimodal anti-protease and immuno-modulator with superior therapeutic effects and a new inhaler device. The technology platform has been established and preclinical proof-of-concept has been shown. The first clinical study in non-CF bronchiectasis is planned to start in 2025.

Biotechnology

AC BioScience SA

Epalinges, Switzerland

Wed 28 Feb · 11:50 – 10:30

AC BioScience, after years of intensive research into its two legacy oncology molecules, has achieved a breakthrough discovery with its new immunomodulating molecule ACB2112. In combination treatments with Immune Checkpoint Inhibitors, ACB2112 potentiates the therapeutic benefits in resistant mouse models (CT26) in colorectal cancer. Its unique Mechanism of Action is effectively targeting the main mechanisms of immune escape and is enabling MSI-L/MSS patients to respond to therapy.

Given the outstanding anti-tumor results of ACB2112 in murine colorectal cancer experiments in November 2023, the company now focuses all its pre-clinical efforts to fast-track pharmaceutical development of this drug.

The drug represents a potential new standard of care for patients with colorectal and possibly other cancers with has a huge market potential. It is secured by composition-of-matter and application patents in oncology and other applications.

The company now raises CHF 5M to progress our lead molecule to the clinic.

Biotechnology

ActiTrexx GmbH

Mainz, Germany

Wed 28 Feb · 14:20 – 10:30

We are a clinical Phase I/II biotech company focused on the development of a platform technology for cellular and biologic therapies to treat overshooting T cell mediated autoimmune and autoinflammatory diseases with high medical unmet needs.

Our cell therapeutic approach is unique being ready to use within 24 hrs (ultrafast manufacturing process), is very cost efficient and IP protected.

With our lead cellular product, Actileucel (activated regulatory T cells), our goal is to prevent GvHD at an early stage and to provide a curative therapy with few side effects for patients undergoing blood stem cell transplantation for the first time. Actileucel is a safe and efficient treatment option that addresses a significant unmet medical need. First patients have been treated with a very good safety profile.

Actileucel has the potential to overcome current risks and limitations inherent in stem cell transplantation.

In addition, due to our platform technology Actileucel has a very high upside potential.

Biotechnology

Atamyo Therapeutics SAS

Evry-Courcouronnes, France

Wed 28 Feb · 12:20 – 10:30

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for muscular dystrophies and cardiomyopathies. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo has a clinical-stage pipeline with first-in-class vectors which include new capsids, new promoters, and organs-detargeting technologies: - ATA-100 is in phase 1b/2b in LGMD-R9/LGMD2I associated to deficiencies in the protein FKRP. - ATA-200 has received clinical trial clearance for LGMD-R5 related to deficiencies in γ-sarcoglycans, - ATA-300 is in IND-enabling studies and targets LGMD-R1/ LGMD2A or calpainopathy; - The cardiomyopathy programs pursues several targets in Dilated Cardiomyopathies Atamyo’s seasoned management has a unique expertise in developing biotech products from Research to late stage clinical development: - Stephane Degove, its CEO, is a biotech entrepreneur with 25 years’ experience in pharma/biotech and strategy. - Isabelle Richard, PhD, its Chief Scientific Officer, heads the Muscular Dystrophy department at Genethon and a pioneer in the research on gene therapy targeting muscular distrophies. - Dr Sophie Olivier, its Chief Medical Officer, has extensive clinical development experience in large and small pharma organizations and has overseen multiple regulatory interactions with both the FDA and the EMA, particularly in regard to pediatric development and rare diseases. - Catherine Cancian, its Chief Technical Officer, has 25 years CMC development in biologics, including gene therapy. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

Biotechnology

Bioxodes SA

Gosselies, Belgium

Wed 28 Feb · 16:10 – 10:30

Bioxodes SA is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. The company’s lead asset, BIOX-101, is a first-in-class drug candidate being developed to treat stroke. BIOX-101’s unique dual mechanism of action is the foundation of an innovative pipeline of drug candidates for treatment and prevention of thromboinflammatory diseases. Worldwide, Bioxodes holds both granted and pending patents associated with BIOX-101.

BiotechnologyPharmaceuticals/Licensing

Eleva GmbH

Freiburg, Germany

Wed 28 Feb · 16:30 – 10:30

Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that have been too challenging to manufacture using other approaches. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, CPV-104 recombinant human complement Factor H, is in Phase 1b testing to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease.

Biotechnology

FoRx Therapeutics AG

Basel, Switzerland

Wed 28 Feb · 14:10 – 10:30

FoRx Therapeutics is a preclinical-stage company dedicated to the discovery and development of innovative, next-generation oncology drugs that target DNA Damage Response (DDR) pathways in cancer. Our lead program is a potent and selective PARG inhibitor (FORX-428) with strong evidence for best-in-class potential, which was recently declared as Development Candidate and is currently progressing to IND.

Humanetics Corporation

Wed 28 Feb · 11:10 – 10:30

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Humanetics entered the field of radiation modulators through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). AFRRI's mission is the discovery and early development of drugs that can protect warfighters from the harmful effects of radiation. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from the Department of Defense to Humanetics. In the ensuing years, the Company has progressed this program into clinical stage with a primary focus on improving the treatment outcomes for patients receiving radiation treatment of solid tumors. Humanetics has three open INDs for BIO 300. We have active clinical programs focused on medical countermeasures, solid tumor radiotherapy and in COVID-19. The Company has recently received a $20 million grant from the DoD for BIO 300.

BiotechnologyPharmaceuticals/Licensing

Innovent Biologics

Suzhou, China

Wed 28 Feb · 11:00 – 10:30

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Sanofi, Incyte, Adimab and LG Chem.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

Legacy Healthcare

Wed 28 Feb · 11:20 – 10:30

Legacy Healthcare is a Swiss-based biotech, with a European/US management team. Its first drug candidate, Coacillium, has been filed for approval with EMA for the treatment of moderate to severe alopecia areata (AA), a debilitating autoimmune disease characterized by random, disfiguring hair loss, with possible life-long relapses. Approval in Europe could occur in Q4 2024 and interactions with the FDA are ongoing. Two oral JAK inhibitors, Olumiant (Eli Lilly) and Litfulo (Pfizer), have been recently approved for the treatment of AA, representing a major advance. However, the toxicity profile of these immunosuppressant drugs restricts their use to patients with a severe form of the disease only, banning early intervention. The safety of Coacillium on the opposite allowed also to include, in addition to severe AA patients, patients at an earlier stage of the disease (moderate AA), giving a chance to prevent disease progression, and increasing the patient base by 4-fold. Coacillium has shown to normalize both endothelial cells activation - without immune-suppressant effect - and hair follicle cycling, two relevant targets in AA and other immune-dermatology diseases and in a Phase 2-3 registration trial, Coacillium cutaneous solution was superior to placebo after 24 weeks of treatment, both in terms of clinical efficacy and improvement of quality of life. It was well tolerated as expected. More importantly, most Coacillium-responders continued to improve after treatment discontinuation, during the 24 weeks treatment-free follow-up period of the study, supporting a possible disease-modifying effect. Based on the product profile, third-party research showed that US payors are willing to reimburse Coacillium in line with oral JAK inhibitors in AA, at $3,000 per month of treatment. In addition, the product being efficacious, the safest, and requiring no follow-up, physicians’ intention to prescribe was high. The potential annual peak-sales have been forecasted at several billion USD.

BiotechnologyPharmaceuticals/Licensing

LIfT BioSciences Ltd.

London, United Kingdom

Wed 28 Feb · 12:00 – 10:30

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. Technology Immuno-Modulatory Alpha Neutrophil progenitors (IMANs) produced from iPSCs or HSCs using our N-LIfT Platform Stage Pre-clinical work completing, IND filing Focus Solid Tumours with high unmet medical need, starting with SCC-NSCLC, PDAC, HNSCC, UCC Patents 2016 Filing Granted, 6 Patents with FTO Current Raise £25m+ Series A. Pharma license discussions underway. Recent Achievements - Successful production from iPSCs and GMP ready production from HSCs at 10L - Increase T-cell and NK cancer killing 250% in Lab-on-chip tumour model - Unmodified IMANs shows comprehensive solid tumour organoid killing (superior to Keytruda & Abraxane) in NSCLC, PDAC - HER-2 CAR IMANs increase cancer cell killing x5 over the already potent unmodified LIfT IMANs have preclinical validation of all of the characteristics required to overcome the challenges to achieving sustained remission in solid tumours.

Biotechnology

Mabylon AG

Schlieren, Switzerland

Wed 28 Feb · 11:30 – 10:30

Mabylon, a Swiss Biotech company, builds on its understanding of antibody responses in allergic patients to develop single multispecific antibody molecules that neutralize the allergens and prevent allergic reactions. The first of such products, MY006, is a potent trispecific antibody with half-life extension being developed for peanut allergy and poised to start clinical trials this year. MY006 is designed to provide rapid, safe, and long-lasting protection against peanut allergen exposure. A clinically-validated MoA and a high-yielding and stable product produced by Pfizer, offer together a greatly de-risked development path. The focus of our current fundraising is to show efficacy POC in a phase 1b, an inflection point rendered even more valuable by the adoption of the same endpoint in early and late clinical development. Shortly following, MY010 and MY011 target multiple tree pollens or grass pollens respectively, to relief seasonal allergy symptoms with one single injection before start of the season. Mabylon is positioned to revolutionize the allergy therapeutic landscape by providing effective therapies with simple dosing, allowing allergic patients to regain control of their lives.

MRM Health

Wed 28 Feb · 14:00 – 10:30

MRM Health is a clinical-stage biotech in inflammatory, CNS and metabolic diseases, with recent positive data in phase 2a clinical trial with MH002 in Ulcerative Colitis.

Ochre Bio

Wed 28 Feb · 14:40 – 10:30

Ochre Bio is a preclinical biotechnology company developing a pipeline of novel RNAi therapeutics for chronic liver disease and it's complications.

Biotechnology

PDC*line Pharma SA

Liege, Belgium

Wed 28 Feb · 11:40 – 10:30

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised close to €61M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia.

Secarna Pharmaceuticals GmbH & Co. KG

Wed 28 Feb · 12:10 – 10:30

Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. With its proprietary ASO platform, the Company is developing molecules with significantly improved efficacy and a comprehensive safety profile, addressing targets that are difficult to reach therapeutically with conventional approaches. Several technologies have been successfully applied to enhance delivery at the target organ or cell type. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities.

STALICLA SA

Switzerland

Wed 28 Feb · 16:40 – 10:30

STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental (NDD) and wider neuropsychiatric disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 30 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government with discussions underway for out-licensing. We are currently raising a series C of $60m to recite the Phase 2 precision autism program development.

Biotechnology

TauC3 Biologics Limited

Stevenage , United Kingdom

Wed 28 Feb · 16:00 – 10:30

TauC3 Biologics is developing a disease-modifying treatment for tauopathies, including frontotemporal dementia due to tau pathology (FTD-tau) and progressive supranuclear palsy (PSP). Tauopathies are devastating and ultimately fatal neurodegenerative diseases typically manifesting as progressive dementia or movement impairment. Brain examination reveals abnormal deposits of tau protein that are believed to be preceded by toxic, soluble forms that lead to neuronal death. Currently in preclinical development, the company’s therapeutic candidate, TBL-100, is a humanized monoclonal antibody that uniquely targets a truncated form of tau known as tauC3 that appears to be highly elevated in these conditions. TauC3, is by far the most noxious form of tau due to its heightened propensity to aggregate, promote spread of tau pathology through the brain, and impair the delivery of mitochondria and other essential cellular constituents to synapses. TauC3’s ability to cause normal tau to aggregate confers enormous potential amplification causing extensive cellular damage. TBL-100 has 1000-fold specificity for tauC3 compared to normal tau and is believed to act at least in part by promoting clearance of tauC3 from the brain. In addition to its therapeutic potential, TBL-100’s specificity may enable use as a diagnostic agent for tauopathies, a critical tool that is currently lacking.

Bringing together world-class expertise and drug development talent to turn its vision into a reality, TauC3 Biologics is poised for efficient preclinical development and subsequent early clinical development, with the aim of rapidly demonstrating safety and proof of concept.

TOLREMO Therapeutics AG

Basel, Switzerland

Wed 28 Feb · 13:40 – 10:30

TOLREMO therapeutics’ mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound, TT125-802, is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.

Urania Therapeutics

Wed 28 Feb · 16:20 – 10:30

Urania Therapeutics is developing small-molecule drug candidates targeting the human ribosome for the treatment of genetic diseases and cancers caused by nonsense mutations.

Vandria SA

Switzerland

Wed 28 Feb · 13:50 – 10:30

Vandria is a clinical-stage biotech company based in Lausanne, Switzerland, developing first-in-class therapies targeting mitochondrial dysfunction to treat age-related diseases. Our lead compound, VNA‑318, is a brain-penetrant mitophagy inducer currently in Phase 1 clinical trials for neurodegenerative conditions. Backed by over $30 million in Series A funding and supported by European innovation grants, Vandria aims to restore cellular resilience and improve health span through mitochondrial science.

RISING BIOTECH STARS SESSIONS:

Adoram Therapeutics SA

Grand Lancy, Switzerland

Thu 29 Feb · 15:00 – 10:30

Adoram Therapeutics, a University of Geneva spin-off, is developing next-generation (allosteric) small molecule drugs, which are safer and more effective than conventional (orthosteric) small molecules. We have developed an allosteric screening platform to efficiently identify positive or negative modulators of GPCR drug targets. We are securing investments to progress two preclinical stage assets towards human trials, and to expand our pipeline.

Biotechnology

AKIGAI AS

Oslo, Norway

Thu 29 Feb · 15:00 – 10:30

AKIGAI will disrupt the field of neuropathic pain (NP) by 2027. With 4 layers to protect our EGFR inhibitor (EGFR-I) in the market, AKIGAI will reposition EGFR-Is, well known cancer drugs, for the treatment of NP. Founders are oncologists, who serendipitously observed dramatic NP relief by EGFR-Is in the clinics. We have rarely witnessed such dramatic and meaningful drug effects as by treating patients with 11 different NP entities at 10 different hospitals. We have off-label and randomized phase-II proof-of concept data from 100+ successfully treated patients. Evidence from 8 different NP rodent models confirmed the effect and uncovered the MoA: Selective translocation of ion channeles on damaged pain fibers. AKIGAI is aiming at an orphan designation from the EMA in May-24, followed by a pivotal trial and rapid upscaling into other NP entities.

AKIGAI AS

Akribion Genomics AG

Thu 29 Feb · 15:00 – 10:30

Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cell depletion via RNA biomarker recognition. The nuclease can target a wide variety of cancer indications defined by genetic make up of patients and can also be applied beyond oncology. The nucleases are protected by a s trong IP position with FTO and the key patent granted in September 2023. The technology had initially been developed within and the company is a spin out of BRAIN Biotech, a stock listed industrial Biotech player that focuses on industrial applications.

Encelta AG

Thu 29 Feb · 15:00 – 10:30

At Encelta, we are revolutionising cancer care by addressing the critical need for robust T cell therapy. Many cancer patients face compromised immune systems and dysfunctional T cells. To combat this challenge, we've pioneered an off-the-shelf T cell product that is safe and effective. What sets us apart? We've engineered T cells that are free from life-threatening GvHD, allowing for universal donor-to-patient compatibility. Our T cell product seamlessly integrates with all approved T cell engagers (TCEs) and over 100 molecules currently in clinical trials. We have successfully conducted studies on cancer cell lines and primary human tumors. We have scaled up manufacturing from a few million to over 100 million T cells and have successfully completed our preliminary in vivo studies in mice.

Epicelya Therapeutics AG

Thu 29 Feb · 15:00 – 10:30

Epicelya Therapeutics is a biotech startup working with two RNA-technology platforms. Platform 1 enables the control of gene expression in cells by selectively activating or deactivating specific genes. This is achieved by accurately targeting specific loci on the genome and modifying the chromatin structure through epigenetic changes, with effects lasting for weeks to months. The platform also incorporates genome-wide screening capabilities, facilitating the discovery of novel target loci in disease model systems. Our team includes experts in epigenetics within primary cells and tissues, who have pioneered advanced technologies in the field. Platform 2 offers the capability to eradicate cancer cells through a novel autonomous mechanism, specifically by targeting a DNA-encoded marker, such as a point mutation or fusion protein present in the cancer cell. This method does not require a disease driver and operates independently of any molecular pathway, ensuring high specificity. As a stealth technology, its discovery remains unknown to the public at present the technology offers the potential to address a wide spectrum of previously undruggable and non-curable pathologies. We are composed of a small yet highly experienced team and have developed a pipeline of selected applications for both platforms. Our IP is well-managed and continually expanded.

eversyn

Thu 29 Feb · 15:00 – 10:30

eversyn provides a platform for the glycoengineering of next-generation biopharmaceuticals. The platform is scalable to production scales.

Biotechnology

EvlaBio AG

Zürich, Switzerland

Thu 29 Feb · 15:00 – 10:30

EvlaBio is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity.

Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.
We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design.

Biotechnology

FluoSphera SA

Plan-les-ouates, Switzerland

Thu 29 Feb · 15:00 – 10:30

FluoSphera is transforming drug discovery with its groundbreaking human systemic in vitro platform. FluoSphera’s cutting-edge technology provides drug developers with unparalleled insights, enabling them to make data-driven decisions about which molecules to prioritize for clinical development. By improving efficiency, FluoSphera’s platform helps save time, reduce costs, and significantly minimize reliance on animal testing.

Biotechnology

Fusix Biotech GmbH

Munich, Germany

Thu 29 Feb · 15:00 – 10:30

Fusix Biotech is an early-stage university spinout based in Munich, Germany. They are developing a completely novel, synthetic oncolytic virus platform that offers potent tumor cell killing via a unique mechanism of action, modulatory activity in the tumor microenvironment and induction of systemic anti-tumor immunity, and optimal gene delivery in an all-in-one therapeutic approach that is delivered intravenously for solid tumors. Their pipeline of "armed" vectors are effective as standalone therapies or as components in combinatorial immunotherapy approaches. Fusix is currently raising a Seed financing round in order to bring its lead development candidate to IND-readiness. They are interested in meeting relevant potential investors and strategic partners.

BiotechnologyPharmaceuticals/Licensing

Hêmera srl

VERONA, Italy

Hemera, a spin-off of the University of Verona and the University of Milan, was established in 2021 as a pioneering biotech company specializing in regenerative medicine for neurological diseases. Our primary objective is to accelerate the clinical development of an autologous cell therapy aimed at nervous tissue regeneration, with a primary focus on spinal cord lesion treatment.

Spinal cord injuries pose a significant challenge as there is currently no cure, profoundly impacting the lives of affected individuals and incurring substantial social, healthcare, emotional, and familial costs. In response to this unmet medical need, Hemera has developed REMaST®, a novel therapy utilizing specialized immune cells called macrophages. These cells are cultured in vitro to optimize their pro-regenerative potential, even within the hostile microenvironment of damaged spinal cords.

Driven by a team of scientists, senior managers and serial lifescience entrepreneurs, including our esteemed co-founders Dr. Ilaria Decimo, Francesco Bifari, Guido Fumagalli, and Massimo Locati, Hemera's innovative approach has shown promising results in preclinical studies, both in vitro and in vivo, on small animals. These findings provide a robust scientific foundation for further investigation into REMaST®'s potential applications, particularly in cases where motor recovery is deemed impossible.

Currently, REMaST® is undergoing an observational study phase, with 3 patients enrolled across five renowned spinal cord injury treatment centers in Italy. Our ultimate goal is to restore autonomy and significantly improve the quality of life for individuals affected by spinal cord trauma. Hemera is committed to advancing groundbreaking therapies that offer hope and tangible benefits to patients in need.

Phialogics AG

Thu 29 Feb · 15:00 – 10:30

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision.

Prolevi Bio AB

Thu 29 Feb · 15:00 – 10:30

Prolevi Bio is a preclinical-stage Swedish start-up with a founding and operational team comprising of pharmacists, fundamental and clinical scientists and serial entrepreneurs. The company’s primary assets include formulations for challenging active pharmaceutical compounds. As our first product we have developed a thyroid hormone formulation for hypothyroid patients that mimics circadian rhythm (natural release cycles).

Biotechnology

PROSION Therapeutics

Cologne, Germany

Thu 29 Feb · 15:00 – 10:30

PROSION pioneered the first approach capable of disrupting the most common communication between disease relevant proteins, making many well-known undruggable targets finally druggable. They call it the ProM technology.

RNATICS GmbH

Thu 29 Feb · 15:00 – 10:30

RNATICS develops nucleic acid therapies targeting disease-causing RNAs in tissue resident macrophages of the lung via inhalation. The primary indications are inflammatory lung diseases with subsequent fibrotic lesions induced by viral infections or volatile toxic substances. The proprietary technology enables efficient delivery of oligonucleotides specifically to lung macrophages through receptor-ligand interaction. This allows for the first time to address the underlying disease biology of lung hyperinflammation beyond symptomatic treatment. The lead candidate RCS-21 is an antisense oligonucleotide against miR-21 coupled to the macrophage-targeting moiety. miR-21 has been validated as promising target for therapeutic intervention in pulmonary inflammation in preclinical proof-of-concept studies in a human as well as mouse context. IND-enabling work is being finalised, and we aim to begin first-in-human clinical trials this year.

StemInov SAS

Thu 29 Feb · 15:00 – 10:30

Our goal is to bring the benefits of Wharton Jelly Mesenchymal Stromal Cells (WJ-MSC) as fast as possible to patients; We advance proprietary cell therapy programs such as septic shock & ARDS. We also plan to partner with leading initiatives from industrial and academic fields through licenses thanks to our innovative technology platform. Our most advanced therapy is Whartsep, the 1st affordable, large-scale and off-the-shelf, WJ-MSC cell therapy that tackles the full complexity of septic shock and ARDS (patented) through unique immuno-modulative and adaptive mode of action.

VALANX Biotech GmbH

Thu 29 Feb · 15:00 – 10:30

Through the power of synthetic biology and genetic code expansion we have developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest. Based on this platform we are developing a number of cutting-edge biologics towards potential treatments for various indications. Our technology is market-leading in speed, purity and conjugation yield and enables the development of the next generation of Antibody-Drug-Conjugates and protein conjugates in general.